[Abstract] Objective: to study the clinical effect and safety of quetiapine fumarate tablets in the treatment of schizophrenia. Methods: 100 patients with schizophrenia were randomly divided into observation group and control group, 50 cases in each group. The control group was treated with oral olanzapine tablets, and the dosage was changed according to the therapeutic effect. The experimental group was treated with quetiapine fumarate tablets on the basis of the control group, the dosage change was the same as the control group. To observe the efficacy, cognitive function and adverse reactions of patients. Results: the total effective rate was 95.37 % in the experimental group, which was higher than that in the control group ( 79.05 % ) ( p < 0.05 ). Before treatment, there was no significant difference in cognitive function between the two groups ( p > 0.05 ). After treatment, the cognitive function score of the two groups was significantly higher than that of the same group before treatment, and increased gradually with the treatment time, and the observation group was higher than the control group, the difference was statistically significant ( p < 0.05 ); The total incidence of adverse reactions in the experimental group was 12.0 %, which was lower than that in the control group ( 32.0 % ) ( p < 0.05 ). Conclusion : the quetiapine fumarate tablets have a better therapeutic effect on schizophrenia, and the safety is relatively high, which is worthy of clinical promotion.
【Key words】
Key wordsQuetiapine fumarate;Schizophrenia;Cognitive function